Review

The developments in paradigm of prostate cancer in recent years
  • Sertaç Yazıcı
  • Halil Kızılöz
  • Haluk Özen
Bull Urooncol 2014; 13: 1-7
  • Tibet Erdogru
Bull Urooncol 2004; 3: 2-9
  • Ender Özden
  • Mert Günay
  • Ahmet Sahin
Bull Urooncol 2005; 4: 3-6
PSA: past, today and tomorrow
  • Levent Mert Günay
  • Sertaç Yazıcı
  • Haluk Özen
Bull Urooncol 2011; 10: 5-10
  • Tibet Erdogru
Bull Urooncol 2005; 4: 7-11
An update on palliative therapy in advanced prostate cancer
  • Kaan Özdedeli
  • Uğur Kuyumcuoğlu
Bull Urooncol 2014; 13: 8-14
Prevalance of BPH: national realities
  • İbrahim Dönmez
  • N. Aydın Mungan
Bull Urooncol 2011; 10: 11-14
Current analysis of urinary biomarkers for prostate cancer
  • Faruk Yencilek
  • Hakan Koyuncu
Bull Urooncol 2011; 10: 11-16
Prostate cancer, screening and diagnosis according to EAU and AUA 2013 updates and practical considerations
  • Tünkut Doğanca
  • Can Öbek
Bull Urooncol 2014; 13: 15-20
Can prostate cancer be prevented?
  • İlkan Yüksel
  • Mustafa Kaplan
Bull Urooncol 2011; 10: 17-21
Preoperatif nomogramlar radikal prostatektomi kararı vermekte etkin oluyor mu?
  • Cenk Acar
  • Saadettin Eskiçorapçı
Bull Urooncol 2010; 9: 18-25
The role of surgery for high-risk prostate cancer
  • Oktay Üçer
  • Talha Müezzinoğlu
Bull Urooncol 2014; 13: 21-24
Does inhibition of inflammation help in preventing prostate cancer ?
  • Ali İhsan Arık
  • Ahmet Güdeloğlu
  • Cemil Uygur
Bull Urooncol 2011; 10: 22-26
Does the Future of Prostate Cancer Treatment Lie with Apoptotic Inducers?
  • Dr. Ece Konaç
  • Dr. Sinan Sözen
Bull Urooncol 2017; 16: 22-27 DOI: 10.4274/uob.606
Lympadenectomy in prostate cancer
  • Murat Koşan
Bull Urooncol 2014; 13: 25-28
Acute urinary retention and surgical risk in BPH
  • Fuat Kızılay
  • Adnan Şimşir
  • İbrahim Cüreklibatır
Bull Urooncol 2011; 10: 27-29
The effect of trace elements in prostate cancer
  • İlker Çelen
  • Feriye Şenol
  • Talha Müezzinoğlu
Bull Urooncol 2011; 10: 27-32
Comparing outcomes of external radiotherapy modalities for prostate cancer
  • Şefik İğdem
Bull Urooncol 2014; 13: 29-32
Has DNA methylation any impact in prostate cancer diagnosis?
  • Buket Kosova
  • Rukiye Özel
  • Çağdaş Aktan
Bull Urooncol 2011; 10: 33-40
In which fields intermittent androgen deprivation therapy can be used in 2014?
  • Yasin Ceylan
  • Bu¨lent Gu¨nlu¨soy
Bull Urooncol 2014; 13: 33-36
Radikal prostatektomi teknikleri arasında üroonkolojik sonuçlar açısından fark var mı?
  • Gökhan Faydacı
  • Uğur Kuyumcuoğlu
Bull Urooncol 2010; 9: 37-40
Open surgery is still gold standard for radical prostatectomy
  • Polat Türker
  • Levent Türkeri
Bull Urooncol 2014; 13: 37-40
Current role of open prostatectomy in Turkey
  • Uğur Kuyumcuoğlu
  • Kaan Özdedeli
Bull Urooncol 2011; 10: 40-43
Active Surveillance: Treatment Modality that Expect Attention for Localized Prostate Cancer
  • Tayyar Alp Özkan
  • Özdal Dillioğlugil
Bull Urooncol 2014; 13: 41-45
KTP laser prostatectomy: is it still trendy?
  • Ahmet Rüknettin Aslan
  • Feridun Şengör
Bull Urooncol 2011; 10: 44-47
Positron emission tomogrphy in prostate carcinoma
  • Recep Bekiş
Bull Urooncol 2014; 13: 46-49
A critical analysis of surgical curative treatments options in localised prostate cancer: open, laparoscopic, and robotassisted radical prostatectomy
  • Ender Özden
  • Yakup Bostancı
  • Yarkın Kamil Yakupoğlu
Bull Urooncol 2011; 10: 47-50
Diagnosis and management of the strictures after prostatectomy
  • Murat Akand
  • Serdar Göktaş
Bull Urooncol 2011; 10: 48-51
The role of 5α-reductase inhibitors on prevention and hormonal treatment of prostate cancer
  • Bülent Öztürk
  • Tufan Çiçek
Bull Urooncol 2014; 13: 50-53
Algorithmic approach to rising PSA after curative prostate cancer treatment
  • Levent Mert Günay
  • Şevket Tolga Tombul
  • Bülent Akdoğan
Bull Urooncol 2011; 10: 51-55
The influence of age on localized prostate cancer: Surgical result of patients over 70 years
  • Erdal Benli
  • Ali Ayyıldız
Bull Urooncol 2014; 13: 54-57
Could focal therapy in prostate cancer replace standard therapy in the future?
  • Saadettin Y. Eskiçorapçı
  • Cihan Toktaş
Bull Urooncol 2011; 10: 56-62
Outstanding variations in the treatment of prostate cancer bone metastases
  • İbrahim Cüreklibatır
Bull Urooncol 2014; 13: 58-62
Neoadjuvant and adjuvant treatment modalities for prostate cancer
  • Erkan Erkan
  • Gökhan Toktaş
Bull Urooncol 2011; 10: 63-69
How affected Active Surveillance the quality of life in low-risk localized prostate cancer?
  • İlker Çelen
  • Sinharib Çitgez
  • Talha Müezzinoğlu
Bull Urooncol 2014; 13: 63-66
The importance of cellular androgenic hormonal mechanisms in treatment and progression of prostate cancer
  • Bertrand Tombal
Bull Urooncol 2013; 12: 65-70
A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”
  • İlker Tinay
  • Levent Türkeri
Bull Urooncol 2016; 15: 65-68 DOI: 10.4274/uob.434
Post prostatektomi inkontinans: Nasıl tedavi edelim?
  • Ahmet Rüknettin Aslan
  • Feridun Şengör
Bull Urooncol 2010; 9: 69-73
Sentinel Lymph Node Biopsy in Lymphadenectomy for Prostate Cancer
  • Cenk Acar
  • Henk van der Poel
Bull Urooncol 2016; 15: 69-75 DOI: 10.4274/uob.625
What is the evidence-based ideal treatment of clinical locally advanced (cT3) prostate cancer?
  • Asıf Yıldırım
  • Erem Kaan Başok
Bull Urooncol 2011; 10: 70-75
Is prostate cancer be screened according to Turkey data?
  • Rahmi Gökhan Ekin
  • Ferruh Zorlu
Bull Urooncol 2013; 12: 71-75
Active surveillance in low risk prostate cancer
  • Ozan Bozkurt
  • Ömer Demir
Bull Urooncol 2013; 12: 76-79
Hormonal treatment of metastatic prostate cancer: Today and future
  • Hasan Soydan
  • Kadir Baykal
Bull Urooncol 2011; 10: 76-81
Magnetic Resonance - Transrectal Ultrasound Fusion Guided Prostate Biopsy
  • Ömer Burak Argun
  • Can Öbek
  • Ali Rıza Kural
Bull Urooncol 2016; 15: 76-79 DOI: 10.4274/uob.635
Treatment options in low-intermediate risk prostate cancer
  • Saadettin Yılmaz Eskiçorapçı
  • Deniz Bolat
Bull Urooncol 2013; 12: 80-85
Immunotherapy in prostate cancer
  • Murat Lekili
Bull Urooncol 2011; 10: 82-84
Nomograms for prostate cancer: which and when to use
  • Saadettin Eskiçorapçı
  • Deniz Bolat
Bull Urooncol 2012; 11: 85-91
Are there any treatment option for metastatic prostate cancer refractory to docetaksel?
  • Yaşar Bedük
Bull Urooncol 2011; 10: 85-89
Radiotherapy in low and intermediate-risk prostate cancer
  • Deniz Yalman
Bull Urooncol 2013; 12: 86-91
Recommendations of Diet and Lifestyle in Prostate Cancer Patients
  • Serdar Çelik
Bull Urooncol 2015; 14: 88-93 DOI: 10.4274/uob.307
Robot-assisted radical prostatectomy: Operative technique — step by step
  • Bora Özveren
  • Levent Türkeri
Bull Urooncol 2013; 12: 92-96
What is the best cutoff value of PSA in detection of prostate cancer
  • Hakan Gemalmaz
Bull Urooncol 2012; 11: 92-95
What is the Approach to Negative Prostate Biopsies?
  • Bora İrer
  • Güven Aslan
Bull Urooncol 2015; 14: 94-96 DOI: 10.4274/uob.310
What are the New Developments in Urinary, Serum and Tissue Biomarkers in Prostate Cancer?
  • Hayrettin Şahin
  • Mehmet Çetinkaya
  • Hasan Deliktaş
Bull Urooncol 2017; 16: 95-100 DOI: 10.4274/uob.620
NON-PSA biomarkers for prostate cancer
  • Yarkın Kamil Yakupoğlu
  • Yakup Bostancı
  • Ender Özden
Bull Urooncol 2012; 11: 96-102
Surgical treatment and/or radiotherapy in high risk prostate cancer
  • Fatih Bıçaklıoğlu
  • Cenk Acar
  • Sinan Sözen
Bull Urooncol 2013; 12: 97-101
Intermittent Versus Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer: Review
  • Mehmet Yıldızhan
  • Mehmet Dündar
  • Mehmet Şirin Ertek
Bull Urooncol 2015; 14: 97-101 DOI: 10.4274/uob.315
Androgene suppression therapy in addition to radical radiotherapy in high risk prostate carcinoma
  • İlknur Bilkay Görken
Bull Urooncol 2013; 12: 102-105
Evaluation of the Current Situation Tissue and Serum Biomarkers in Prostate Cancer
  • Enis Kervancıoğlu
  • Murat Koşan
Bull Urooncol 2015; 14: 102-107 DOI: 10.4274/uob.320
Repeat prostate biopsy: who, when, how?
  • Hayrettin Şahin
Bull Urooncol 2012; 11: 103-107
New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor
  • Yavuz Selim Süral
  • Çağ Çal
Bull Urooncol 2013; 12: 106-110
Current status of pain control in trus-guided prostate biopsy
  • İlker Seçkiner
  • Ömer Bayrak
Bull Urooncol 2012; 11: 108-113
Focal Therapy for Prostate Cancer: Current Status of HIFU
  • Tayyar Alp Özkan
  • Saadettin Eskiçorapçı
Bull Urooncol 2015; 14: 108-112 DOI: 10.4274/uob.321
New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate
  • Bülent Akdoğan
Bull Urooncol 2013; 12: 111-114
Radical Prostatectomy and Lymphadenectomy in the High-Risk Prostate Cancer: Surgical Technique, Functional and Oncologic Outcomes
  • Hayrettin Şahin
  • Hasan Deliktaş
Bull Urooncol 2015; 14: 113-119 DOI: 10.4274/uob.324
Active surveillance for localized prostate cancer
  • İlker Tınay
  • Levent Türkeri
Bull Urooncol 2012; 11: 114-118
New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T
  • Gürbüz Görümlü
  • Erdem Göker
Bull Urooncol 2013; 12: 115-117
New treatment options in castration resistant prostate cancer: denosumab, alpharadin
  • Hakan Gemalmaz
Bull Urooncol 2013; 12: 118-122
Surgical technique of nerve sparing radical prostatectomy and periprostatic field anatomy
  • Ali Cansu Bozacı
  • Bülent Akdoğan
  • Haluk Özen
Bull Urooncol 2012; 11: 119-123
Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer
  • Mehmet Yıldızhan
  • Hakan Gemalmaz
  • Mehmet Şirin Ertek
Bull Urooncol 2015; 14: 120-127 DOI: 10.4274/uob.328
Relationship between active surveillance / watchfull waiting and quality of life in localised prostate cancer
  • İlker Çelen
  • Yasin Ceylan
Bull Urooncol 2013; 12: 123-126
Current surgical approaches in local invasive prostate cancer: urologist approach
  • Zafer Kozacıoğlu
  • Bülent Günlüsoy
Bull Urooncol 2012; 11: 124-128
How shoud PSA repalse (rising PSA) be managed after radical prostatectomy? How should treatment algorithms be shaped?
  • İlker Çelen
  • Murat Lekili
Bull Urooncol 2013; 12: 127-131
Active Surveillance in Prostate Cancer
  • Volkan İzol
  • Nebil Akdoğan
Bull Urooncol 2017; 16: 127-132 DOI: 10.4274/uob.820
Prostate Biopsy 2014: TRUS, MRI/TRUS Fusion? Transrectal? Transperineal?
  • Kaan Çömez
  • Ozan Bozkurt
  • Mehmet Uğur Mungan
Bull Urooncol 2015; 14: 128-135 DOI: 10.4274/uob.329
Current treatment approaches in locally advanced prostate cancer: a radiation oncologist perspective
  • Ömür Karakoyun Çelik
Bull Urooncol 2012; 11: 129-133
Radical prostatectomy indications and outcomes in the high-risk localised prostate cancer
  • Hayrettin Şahin
  • Hasan Deliktaş
Bull Urooncol 2013; 12: 132-136
Management of recurrences after radiation therapy used for curative intent in prostate cancer
  • Yılören Tanıdır
  • Levent Türkeri
Bull Urooncol 2012; 11: 134-141
Multiparametric MR in Prostate Cancer: General Practical Application Advices
  • Seçil Mustafa
  • Basara Işıl
  • Altay Canan
Bull Urooncol 2015; 14: 136-143 DOI: 10.4274/uob.330
Salvage radical prostatectomy for locally recurrent prostate cancer following primary radiotherapy
  • Ali Cansu Bozacı
  • Sertaç Yazıcı
Bull Urooncol 2013; 12: 137-141
Management of infravesical strictures after radical retropubic prostatectomy
  • Mustafa Karalar
  • İbrahim Keleş
  • Mutlu Ateş
Bull Urooncol 2012; 11: 142-145
AUA/ASTRO 2013 Guidelines for Adjuvant and Salvage Radiation Therapy After Prostatectomy: What are the Yields and the Changes?
  • Deniz Yalman
Bull Urooncol 2015; 14: 144-149 DOI: 10.4274/uob.339
Laparo-Endoscopic Single Site (LESS) radical prostatectomy: does port number decrease?
  • Bircan Mutlu
  • Volkan Tuğcu
Bull Urooncol 2012; 11: 146-149
Prostate cancer in the era of robotic surgery
  • Çag Çal
Bull Urooncol 2012; 11: 150-155
‘Nanotechnology Applications’ in the Treatment of Prostate Cancer
  • Ali Furkan Batur
  • Kerem Gencer Kutman
  • Mustafa Suat Bolat
Bull Urooncol 2015; 14: 150-155 DOI: 10.4274/uob.375
Immunotherapy for the treatment of castration resistant prostate cancer: sipuleucel-T
  • Güven Aslan
Bull Urooncol 2012; 11: 156-158
Active Surveillance-Factors Affecting the Treatment Decision: 3M: “Marker”, “Mapping”, “MRI”
  • Ender Özden
  • Mehmet Necmettin Mercimek
Bull Urooncol 2015; 14: 156-160 DOI: 10.4274/uob.379
New treatment stragies in metastatic castration resistant prostate cancer: Re-Docetaxel, Abiraterone asetate, Cabazitaxel, MDV 3100
  • Sıtkı Ün
  • Ferruh Zorlu
Bull Urooncol 2012; 11: 159-163
Information about Prostate Cancer for Urologist: Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scintigraphy
  • Levent Kabasakal
Bull Urooncol 2016; 15: 159-162 DOI: 10.4274/uob.616
Rising Psa After Radical Prostatectomy: Radiotherapy in High Risk Group: Early? Late?
  • Gül Alço
  • Sefik İğdem
Bull Urooncol 2015; 14: 161-164 DOI: 10.4274/uob.387
Active Surveillance in Prostate Cancer: Can We Expand the Indications?
  • Hacı Murat Akgül
  • Asgar Garayev
  • İlker Tinay
Bull Urooncol 2016; 15: 163-166 DOI: 10.4274/uob.619
Update in the management of skeletal related events for metastatic prostate cancer: Denosumab, Alfaradin
  • Serdar Çelik
  • Uğur Mungan
Bull Urooncol 2012; 11: 164-167
The significance of tertiary Gleason pattern in prostate cancer
  • H. Hüseyin Tavukçu
  • Polat Türker
Bull Urooncol 2012; 11: 168-172
Nursing interventions in patients receiving Taxan Chemotherapy
  • Yeter Kırdal
Bull Urooncol 2012; 11: 173-177
Liquid Biopsy: Circulating Tumor Cells and its Impact on Follow-up/Treatment of Prostate Cancer Patients
  • İbrahim Kulaç
Bull Urooncol 2014; 13: 196-200 DOI: 10.4274/uob.159
Metabolic Syndrome and Benign Prostate Hyperplasia: An Update
  • İlker Tınay
  • Hacı Murat Akgül
  • Yılören Tanıdır
Bull Urooncol 2014; 13: 206-209 DOI: 10.4274/uob.162
Interventional Treatment of Benign Prostatic Hyperplasia on Elderly People: Prostatic Stent and Prostatic Arterial Embolization
  • Eray Hasırcı
  • Mehmet İlteriş Tekin
Bull Urooncol 2014; 13: 210-214 DOI: 10.4274/uob.166
Laparoscopic Simple Prostatectomy
  • Kadir Ömür Günseren
  • Yakup Kordan
  • Hakan Vuruşkan
Bull Urooncol 2014; 13: 215-222 DOI: 10.4274/uob.174
Molecular Biology in Diagnosis and Treatment of Prostate Cancer
  • Ece Konaç
  • Sinan Sözen
Bull Urooncol 2014; 13: 228-235 DOI: 10.4274/uob.194
Robotic Prostatectomy: Is it More Advantageous Regarding Quality of Life?
  • Olcay Yıldırım
  • Kamil Çam
Bull Urooncol 2014; 13: 241-243 DOI: 10.4274/uob.200
Current Situation in the Use of 5-Alpha Reductase Inhibitors for Prostatic Diseases
  • Murat Koşan
Bull Urooncol 2014; 13: 244-246 DOI: 10.4274/uob.212
Could We Reach the Standard Treatment of Lower Urinary Tract Symptoms/Benign Prostate Hyperplasia?
  • Eray Hasırcı
  • Murat Koşan
Bull Urooncol 2014; 13: 247-251 DOI: 10.4274/uob.219
Monopolar and Bipolar Modalities of Transurethral Prostate Resection
  • Hikmet Köseoğlu
  • Ramazan Yavuz Akman
Bull Urooncol 2015; 14: 296-298 DOI: 10.4274/uob.245
Genetic Basis of Benign Prostatic Hyperplasia Etiology
  • Cüneyt Özden
  • Cevdet Serkan Gökkaya
Bull Urooncol 2015; 14: 299-302 DOI: 10.4274/uob.470
The Effects of Hormonal Therapy on Quality of Life in Prostate Cancer
  • Yusuf Şenoğlu
  • Kamil Çam
Bull Urooncol 2015; 14: 317-320 DOI: 10.4274/uob.463

Article - Comment

“Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911)
  • Esin Yildiz
Bull Urooncol 2006; 5: 19-21
Can effect of finasteride on prostate-specific antigen be used to decrease repeat prostate biopsy?
  • Sadik Görür
  • Murat Bozlu
Bull Urooncol 2006; 5: 26-27
  • Rauf Taner Divrik
Bull Urooncol 2005; 4: 26-27
Pathological characteristics of prostate cancer detected through prostate specific antigen based screening
  • Sinan Ekici
Bull Urooncol 2006; 5: 27-29
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance
  • Kadir Baykal
  • Cüneyt Adayener
Bull Urooncol 2006; 5: 27-28
Time to prostate spesific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality
  • Mustafa Kaplan
Bull Urooncol 2006; 5: 28-30
  • N. Aydin Mungan
Bull Urooncol 2005; 4: 28-29
Under diagnosis and over diagnosis of prostate cancer
  • Mustafa Kaplan
Bull Urooncol 2007; 6: 29-33
Finasterid improves the sensitivity of digital rectal examination for prostate cancer detection
  • Ahmet Soylu
Bull Urooncol 2007; 6: 29-31
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794
  • Sefik Igdem
Bull Urooncol 2007; 6: 30-32
The 20-core Prostate Biopsy Protocol- A new Gold Standart?
  • Gökhan Toktaş
Bull Urooncol 2008; 7: 31-34
Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy—a propensity scoring approach
  • Cemil Uygur
Bull Urooncol 2007; 6: 32-33
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
  • Kadir Baykal
  • Hasan Soydan
Bull Urooncol 2007; 6: 33-35
  • Saadettin Yilmaz Eskiçorapçi
Bull Urooncol 2006; 5: 33-34
Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer
  • Recep Büyükalpelli
Bull Urooncol 2007; 6: 36-40
Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer
  • Ahmet Tunçkiran
  • Murat Bozlu
Bull Urooncol 2007; 6: 36-38
Saturation Technique Does Not Decrease Cancer Detection During Followup After Initial Prostate Biopsy
  • Ali İhsan Arık
Bull Urooncol 2008; 7: 38-40
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.
  • Kadir Türkölmez
Bull Urooncol 2008; 7: 41-43
Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review
  • Oğuz Acar
Bull Urooncol 2009; 8: 47-51
Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer
  • Ali F. Şahin
Bull Urooncol 2012; 11: 178-180

About Journal

Forms

Useful Links

Applications